Compare Boston Scientific Corporation (BSX) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs abrdn Physical Palladium Shares ETF — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while abrdn Physical Palladium Shares ETF trades at $23.52. The key difference: abrdn Physical Palladium Shares ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | PALL | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $108.14 | $37.18 |
52-Week Low | $42.63 | $19.96 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.73, down 1.47% with bearish technical signals from moving averages. The ETF faces headwinds from palladium's 47% price decline from January 2026 highs, though recent news highlights potential buying opportunities as the metal approaches technical support levels. A 1:5 stock split occurred on May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook remains cautious due to weak palladium pricing and industrial demand concerns, though some analysts see value at current levels. Key risks include commodity price volatility and Federal Reserve policy impacts. Investment appeal hinges on palladium's supply-demand dynamics improving from current depressed conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
